Xilio Therapeutics, Inc.

In the top alliance by deal value, AbbVie and Xilio Therapeutics entered a collaboration and option-to-license agreement to develop up to four novel tumor-activated, antibody-based immunotherapies, in

A deal with AbbVie and new preclinical data demonstrating the potential of its masked T-cell engagers have helped revive the fortunes of struggling small-cap biotech Xilio Therapeutics. The big pharma

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Gets Xilio’s Phase I Cancer Drug